HgCapital Trust Plc Friday announced that HgCaital (HGT.L) has divested its U.K-based specialty pharmaceutical company, Mercury Pharma, for a total sale consideration of 465 million pounds, to European private equity firm, Cinven.
Mercury Pharma is a speciality pharmaceutical company focused on the sale of niche prescription off-patent products. Mercury Pharma's portfolio is underpinned by strong intellectual property rights with 91% of revenue from
Philipp Schwalber, Head of HgCapital's Healthcare team, said: "Mercury Pharma is the first exit for HgCapital 6, the second realisation by HgCapital's Healthcare Team in the last two years, and the most recent in a long line of public-to-private success stories for HgCapital,,,,,"
Click here to receive FREE breaking news email alerts for HgCapital and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org